CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 10 enrolled
Drug / intervention
Burosumab Injection [Crysvita]drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04146935
NCT04146935Phase 4Completed
CompareCT.gov

Examining the Effect of Burosumab on Muscle Function Using MR Spectroscopy

Yale University·interventional·Posted Oct 31, 2019·Updated Aug 24, 2023

In Brief

A Phase 4 clinical trial evaluating Burosumab Injection [Crysvita] for X-linked Hypophosphatemia. Completed, enrolled 10 participants across 1 site.

Detailed Summary

Patients with X-linked hypophosphatemia (XLH) often report symptoms of fatigue and weakness particularly after exertion, in addition to their skeletal complaints. In previous trials using KRN23 (same drug as burosumab/Crysvita®), patients report these symptoms improve. The investigators wish to test this hypothesis directly by measuring muscle energy when patients begin treatment with Crysvita® for the first time.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsX-linked Hypophosphatemia
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2020202120222023202420252026
First PostedOct 31, 2019
Enrollment StartNov 13, 2019
Primary CompletionAug 25, 2022
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 6.7 years ago

Interventions

Burosumab Injection [Crysvita]drug

Burosumab/Crysvita SC injection monthly